Holen Sie sich die Stockscreener-App
2.01
11.05%
0.20
Handel nachbörslich:
1.99
-0.02
-1.00%
Annexon Inc Aktie (ANNX) Neueste Nachrichten
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) | ANNX Stock News - GuruFocus
Annexon Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Annexon Awards $387K Worth of Stock Options to New Hires: Inside the Compensation Package - Stock Titan
HC Wainwright Issues Negative Estimate for Annexon Earnings - Defense World
HC Wainwright Has Lowered Expectations for Annexon (NASDAQ:ANNX) Stock Price - Defense World
Needham & Company LLC Has Lowered Expectations for Annexon (NASDAQ:ANNX) Stock Price - Defense World
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Annexon (ANNX) Receives Revised Price Target from HC Wainwright - GuruFocus
Schonfeld Strategic Advisors LLC Sells 589,091 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Cantor Fitzgerald maintains Overweight on Annexon stock By Investing.com - Investing.com Nigeria
Annexon (ANNX) Sees Price Target Cut to $14 by H.C. Wainwright | - GuruFocus
Annexon Inc Reports Q1 2025 EPS of -$0.37, Missing Estimates; Re - GuruFocus
Annexon (ANNX) Maintains "Buy" Rating Despite Price Target Cut | ANNX Stock News - GuruFocus
Annexon Biosciences Reports Increased Q1 2025 Losses - TipRanks
Annexon, Inc. SEC 10-Q Report - TradingView
Annexon Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Annexon (ANNX) Advances with Promising Neurological and Vision T - GuruFocus
Annexon (ANNX) Financial Outlook Supported by Strong Cash Positi - GuruFocus
Annexon, Inc. Announces Upcoming FDA Meeting and Progress on Novel Therapies for Neurological and Ophthalmic Diseases - Nasdaq
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones - GlobeNewswire
Hsbc Holdings PLC Has $156,000 Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Dimensional Fund Advisors LP Buys 231,034 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon stock hits 52-week low at $3.04 amid market challenges - MSN
Annexon Announces Presentations on the Clinical Advancement - GlobeNewswire
Annexon (ANNX) Expected to Announce Quarterly Earnings on Monday - Defense World
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting | ANNX Stock News - GuruFocus
Annexon, Inc. Reports Improved Outcomes for Tanruprubart in Guillain-Barré Syndrome at 2025 Peripheral Nerve Society Annual Meeting - Nasdaq
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting - Stock Titan
Annexon Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView
Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress - The Manila Times
Annexon to Present on the Neuroprotective Effects of ANX007 - GlobeNewswire
MetLife Investment Management LLC Boosts Holdings in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Barclays PLC - Defense World
Annexon Biosciences wants to Move GBS Forward in awareness push - Medical Marketing and Media
Invesco Ltd. Acquires 10,611 Shares of Annexon, Inc. (NASDAQ:ANNX) - The AM Reporter
Holdings of Annexon Inc (ANNX) are aligned with the stars - Sete News
What technical indicators reveal about ANNX stock - uspostnews.com
JP Morgan’s latest rating for ANNX stock - knoxdaily.com
Analytical Overview: Annexon Inc (ANNX)’s Ratios Tell a Financial Story - DWinneX
Legal & General Group Plc Acquires 71,665 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Wells Fargo & Company MN Boosts Stock Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Investors in cash trouble should check out Annexon Inc (ANNX) - Sete News
SEC Form DEFA14A filed by Annexon Inc. - Quantisnow
JP Morgan analysts upgrades an Overweight rating for Annexon Inc (ANNX) - knoxdaily.com
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Geode Capital Management LLC - Defense World
ANNX’s price-to-sales ratio: Is it a good investment opportunity? - uspostnews.com
Annexon Inc (ANNX) Stock: A Year of Market Fluctuations - investchronicle.com
Alliancebernstein L.P. Reduces Stock Holdings in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Sees Large Decrease in Short Interest - Defense World
JPMorgan Chase & Co. Has $7.75 Million Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) | ANNX Stock News - GuruFocus
Annexon Strengthens Team with Strategic Equity Package: Inside the $1.54 Share Grant - Stock Titan
Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck (NASDAQ:ANNX) - Seeking Alpha
Vanguard Group Inc. Buys 576,625 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
KLP Kapitalforvaltning AS Takes $98,000 Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
American Century Companies Inc. Has $916,000 Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Biosciences’ ANX005: Promising Phase III Results and Strategic Initiatives Drive Buy Rating - TipRanks
Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder - AOL.com
Why Annexon Inc. (ANNX) Went Down On Thursday? - Yahoo Finance
Annexon Touts ‘Rapid’ and ‘Durable’ Improvements for Targeted Guillain-Barré Therapy - BioSpace
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):